Bladder cancer: number of radical cystectomy procedures performed by a surgeon over a 1 year period. | National Quality Measures Clearinghouse | NHS Scotland

Bladder cancer: number of radical cystectomy procedures performed by a surgeon over a 1 year period. | National Quality Measures Clearinghouse

NHS Scotland

• Bladder cancer: number of radical cystectomy procedures performed by a surgeon over a 1 year period.
• Bladder cancer: proportion of patients with bladder cancer who receive treatment with curative intent (radical cystectomy, radiotherapy and chemotherapy) who die within 30 to 90 days of treatment.
• Bladder cancer: proportion of patients with bladder cancer who undergo primary radical cystectomy where greater than or equal to 10 lymph nodes are resected and pathologically examined.
• Bladder cancer: proportion of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) or cystectomy where pathology report contains all relevant data items.
• Bladder cancer: proportion of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) where a bladder diagram/detailed description with documentation of tumour location, size, number and appearance has been used at initial resection.
• Bladder cancer: proportion of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) where detrusor muscle is included in the specimen at initial resection.
• Bladder cancer: proportion of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) where it is documented whether the resection was complete or not at initial resection.
• Bladder cancer: proportion of patients with high risk non muscle invasive bladder cancer (NMIBC) who have undergone transurethral resection of bladder tumour (TURBT) where detrusor muscle is absent from specimen, who have a second TURBT or early cystoscopy (± biopsy) within 6 weeks (42 days) of initial TURBT.
• Bladder cancer: proportion of patients with high risk non muscle invasive bladder cancer (NMIBC) who have undergone transurethral resection of bladder tumour (TURBT) where initial resection is incomplete, who have a second resection or early cystoscopy (± biopsy) within 6 weeks (42 days) of initial TURBT.
• Bladder cancer: proportion of patients with high risk non muscle invasive bladder cancer (NMIBC) who have undergone transurethral resection of bladder tumour (TURBT) who have a second TURBT or early cystoscopy (± biopsy) within 6 weeks (42 days) of initial resection.
• Bladder cancer: proportion of patients with muscle invasive bladder cancer (MIBC) who are discussed at the multidisciplinary team (MDT) meeting before definitive treatment.
• Bladder cancer: proportion of patients with muscle invasive bladder cancer (MIBC) who have neo-adjuvant chemotherapy who undergo cystectomy or chemoradiation within 8 weeks of treatment.
• Bladder cancer: proportion of patients with muscle invasive bladder cancer (MIBC) who undergo radical cystectomy or radiotherapy only within 3 months of diagnosis of MIBC.
• Bladder cancer: proportion of patients with muscle invasive bladder cancer (MIBC) who undergo radical cystectomy who met with an oncologist prior to radical cystectomy.
• Bladder cancer: proportion of patients with non muscle invasive bladder cancer (NMIBC) who are discussed at the multidisciplinary team (MDT) meeting following initial transurethral resection of bladder tumour (TURBT).
• Bladder cancer: proportion of patients with non muscle invasive bladder cancer (NMIBC) who undergo transurethral resection of bladder tumour (TURBT) who receive a single instillation of mitomycin C within 1 day of initial resection.
• Bladder cancer: proportion of patients with transitional cell carcinoma of the bladder (T2-T4) receiving radical radiotherapy treated concomitantly with chemotherapy.
• Brain and central nervous system (CNS) cancer: proportion of newly-diagnosed patients with brain/CNS cancer discussed at multidisciplinary team (MDT) meeting who have a documented World Health Organisation (WHO) performance status at the time of MDT discussion.
• Brain and central nervous system (CNS) cancer: proportion of patients with a histological diagnosis of brain/CNS cancer where the histological pathology report contains a full set of data items.
• Brain and central nervous system (CNS) cancer: proportion of patients with brain/CNS cancer presenting with seizures at diagnosis who are seen by a neurologist or a nurse with expertise in epilepsy management.
• Brain and central nervous system (CNS) cancer: proportion of patients with brain/CNS cancer undergoing oncological treatment (chemotherapy or radiotherapy) who are managed by a specialist neuro-oncologist.
• Brain and central nervous system (CNS) cancer: proportion of patients with brain/CNS cancer undergoing radical radiotherapy for whom the radiotherapy planning process includes MRI fusion.
• Brain and central nervous system (CNS) cancer: proportion of patients with brain/CNS cancer undergoing surgical resection and/or radical radiotherapy or chemotherapy who receive an MRI prior to treatment.
• Brain and central nervous system (CNS) cancer: proportion of patients with brain/CNS cancer who are discussed at the multidisciplinary team (MDT) meeting before definitive management.
• Brain and central nervous system (CNS) cancer: proportion of patients with glioblastomas undergoing surgery where tissue sample is assessed for the MGMT promoter hypermethylation status within 21 days of surgery.
• Brain and central nervous system (CNS) cancer: proportion of patients with glioma with an oligodendroglial component undergoing surgery where tissue sample is tested for 1p/19q within 21 days of surgery.
• Brain and central nervous system (CNS) cancer: proportion of patients with high grade glioma (World of Health Organisation [WHO] grades III and IV) undergoing surgery who commence their oncological treatment (chemotherapy, radiotherapy, or chemoradiotherapy) within 6 weeks of surgery.
• Brain and central nervous system (CNS) cancer: proportion of patients with malignant glioma (with enhancing component on pre-operative imaging) undergoing surgical resection who receive MRI within 3 days (72 hours) of surgical resection.
• Brain and central nervous system (CNS) cancer: proportion of patients with resectable malignant glioma (with enhancing component on pre-operative imaging) undergoing surgery (biopsy and surgical resection) where greater than 90% reduction in tumour volume is achieved.
• Brain and central nervous system (CNS) cancer: proportion of patients with resectable malignant glioma (with enhancing component on pre-operative imaging) undergoing surgical resection where greater than 90% reduction in tumour volume is achieved.
• Clinical trial access: proportion of patients with cancer who are enrolled in an interventional clinical trial or translational research.